Russian pharmaceutical company Promomed, through its subsidiary Biokhimik, has reportedly secured a compulsory licence to use ViiV Healthcare’s patented technology relating to dolutegravir (DTG), one of the most widely used antiretroviral medicines for HIV treatment.
The decision was issued by Russia’s Ninth Arbitration Court of Appeal, which overturned a July 2026 ruling by the Moscow Arbitration Court rejecting Biokhimik’s application.
The decision is particularly significant because dolutegravir is a cornerstone of modern first-line HIV treatment, including WHO-recommended regimens, and represents a major segment of Russia’s publicly funded antiretroviral market.
According to pharmaceutical industry publication Vademecum, the case concerns Eurasian patent No. 014162, which remains in force in Russia until July 2029. Biokhimik sought authorisation to use the patented invention without the patent holder’s consent, proposing royalty payments equivalent to 1.7% of revenue generated from sales of its generic product.
In July, the court of first instance rejected the application. Promomed had argued that dependence on manufacturers from countries classified by Russia as “unfriendly” created a risk of medicine shortages. However, the Russian Ministry of Health maintained that there was no shortage of dolutegravir and that supplies were sufficient. The court also found that Biokhimik had failed to substantiate the relevant legal and technical grounds for granting the licence.
The appellate court has now reversed that decision. Promomed says its claims were granted in full, although the court’s detailed written reasoning has not yet been published.
Promomed and the Russian DTG market
Promomed is a Russian pharmaceutical group with manufacturing operations centred on Biokhimik, a pharmaceutical plant in Saransk, Republic of Mordovia. The group develops, manufactures and markets prescription medicines, including generics and products based on its own pharmaceutical development programmes.
Promomed registered its generic version of dolutegravir in Russia in 2024. Several other Russian pharmaceutical companies, including R-Pharm and Pharmasyntez, also hold marketing authorisations for dolutegravir products.
According to the expert group Zdravresurs, Russia’s federal procurement campaign for 2026 allocated RUB 8.44 billion to the purchase of dolutegravir (Tivicay). The procurement volume reached 162,086 annual treatment courses, an increase of 10,017 courses compared with 2025. Dolutegravir remains one of the largest expenditure items in Russia’s publicly funded antiretroviral treatment programme, second only to elsulfavirine-based medicines, for which RUB 10.32 billion was allocated in 2026.
Earlier compulsory licence for cabotegravir
The dolutegravir ruling follows another recent legal victory for Promomed. In late October 2026, Biokhimik obtained a compulsory licence covering patents related to cabotegravir, another ViiV Healthcare antiretroviral, including its long-acting injectable formulation.
However, the two cases have different market implications. While cabotegravir represents an important long-acting treatment technology, dolutegravir is already extensively used in routine HIV treatment in Russia, making the latest decision potentially much more consequential for public procurement, competition and access to treatment.
The ruling also raises broader questions about the expanding use of compulsory licensing in Russia, the protection of pharmaceutical patents and the implications for originator companies operating in the Russian market.
Importantly, the court decision does not itself establish that Russia is experiencing a shortage of dolutegravir, nor does it confirm that Promomed has already started commercial production under the newly granted licence.

Leave A Comment